myasthenia gravis Archives -

One of the main assets of Sanofi’s $3.7 billion buyout of Principia Biopharma has run into trouble, after

Liver injuries prompt clinical hold on Sanofi BTK drug

https://pharmaphorum.com/news/liver-injuries-prompt-clinical-hold-on-sanofi-btk-drug/

The UK regulatory authority has cleared the path for some patients with generalised myasthenia gravis (gMG) to get

UK grants early access to Argenx’ efgartigimod for myasthenia gravis

https://pharmaphorum.com/news/uk-grants-early-access-to-argenx-efgartigimod-for-myasthenia-gravis/

Argenx only recently scored FDA approval for its intravenous anti-neonatal FC receptor (FcRn) antibody Vyvgart for generalised myasthenia

With rivals threatening, Argenx scores key myasthenia gravis win

https://pharmaphorum.com/news/with-rivals-threatening-argenx-scores-key-myasthenia-gravis-win/

Belgian drugmaker UCB says it will be able to file not one but two new drug therapies for

UCB preps filings for another challenger to AZ’s Soliris

https://pharmaphorum.com/news/ucb-preps-filings-for-another-challenger-to-azs-soliris/

UCB has the positive result it was hoping for in its phase 3 trial of anti-neonatal FC receptor

UCB chases after Argenx with FcRN drug for myasthenia gravis

https://pharmaphorum.com/news/ucb-chases-after-argenx-with-fcrn-drug-for-myasthenia-gravis/

The FDA has approved Alexion’s Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making

Myasthenia Gravis approval will boost Soliris revenues

https://pharmaphorum.com/news/myasthenia-gravis-approval-will-boost-soliris-revenues/

myasthenia gravis